Pacira BioSciences Returns to Profitability in 2025 with Strong Revenue Growth and Strategic Progress

summarizeSummary

Pacira BioSciences, Inc. achieved GAAP net income of $7.0 million in 2025, reversing a prior-year loss, driven by revenue growth and improved gross margins. The company advanced its strategic goals with new partnerships, product expansions, and a significant share repurchase program, alongside favorable legal outcomes.

check_boxKey Events

• Return to GAAP Net Income

  Reported GAAP net income of $7.0 million for 2025, a significant turnaround from a $99.6 million net loss in 2024.

• Revenue Growth and Margin Expansion

  Total revenues increased 4% to $726.4 million in 2025, with EXPAREL sales up 5% and iovera® up 6%. Gross margin improved by 3 percentage points to 79%.

• Strategic Partnerships and Pipeline Advancement

  Entered a co-promotion agreement with Johnson & Johnson MedTech for ZILRETTA, licensed PCRX-2002 from AmacaThera, and partnered with LG Chem for EXPAREL in Asian-Pacific markets. FDA cleared a new iovera® Smart Tip for chronic low back pain.

• Significant Share Repurchase Program

  Repurchased $151.4 million of common stock in 2025 under a $300 million authorization, with $150 million remaining for future repurchases.

auto_awesomeAnalysis

Pacira BioSciences, Inc. reported a significant financial turnaround in 2025, achieving GAAP net income of $7.0 million, a notable improvement from a $99.6 million net loss in 2024. This performance was supported by a 4% increase in total revenues to $726.4 million and a 3 percentage point expansion in gross margin to 79%. The company also made substantial progress on its strategic 5x30 plan, including expanding its product portfolio through new partnerships and product clearances. Key legal victories, such as the $28.3 million repayment from the RDF royalty dispute and the dismissal of a securities class action, further bolstered financial results. However, the company incurred a $25.9 million impairment charge related to its ZILRETTA shoulder asset and faces ongoing patent litigation for EXPAREL, indicating continued investment and legal defense efforts.